Antihormonal therapy in breast cancer and mTOR inhibitors;Hormonorésistance des cancers du sein et inhibiteurs de mTOR

Bulletin du Cancer

Volumn 98, Issue 12, 2011, Pages 1431-1437

  Heudel, Pierre Étienne ^a   Tredan, Olivier ^a   Ray Coquard, Isabelle ^a   Treilleux, Isabelle ^a   Guastalla, Jean Paul ^a   Bachelot, Thomas ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

Hormonotherapy; Metastatic breast cancer; mTOR inhibitors

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; EVEROLIMUS; GROWTH FACTOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN KINASE B; TEMSIROLIMUS;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER THERAPY; CELL ACTIVATION; HUMAN; REVIEW;

EID: 84855250041     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1496     Document Type: Review

References (28)

1. Institut national de veille sanitaire. Projections de l'incidence et de la mortalité par cancer en France en 2010. http://libbey. fontismedia.com/bdc/index-author.php.
2. Hill C, Jan P, Doyon F. Is cancer mortality increasing in France? Br J Cancer 2001;85:1664-6. (Pubitemid 34081509)
3. Andre F, Slimane K, Bachelot T, et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 2004;22:3302-8. (Pubitemid 41103686)
4. Debled M, Dalenc F, Mauriac L, Brain E. Medical treatments of endocrine-sensitive Her-2 negative breast cancers: a review. Bull Cancer 2011;98:655-70. doi: 10.1684/bdc.2011.1367 (Review French).
5. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
6. De Cremoux P. Molecular prognostic and predictive markers of breast cancer treatment. Bull Cancer 2010;97:1297-304 (Review French).
7. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004;11:643-58. (Pubitemid 40065543)
8. de Graffenried LA, Friedrichs WE, Russell DH, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res 2004;10:8059-67. (Pubitemid 39587547)
9. Boulay A, Rudloff J, Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005;11:5319-28. (Pubitemid 41003721)
10. Coutte L, Dreyer C, Sablin MP, Faivre S, Raymond E. PI3K-AKT-mTOR pathway and cancer. Bull Cancer 2011 [Epub ahead of print].
11. Perez-Tenorio G, Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 2002;86:540-5. (Pubitemid 34185089)
12. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002;1:707-17.
13. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001;276:9817-24.
14. Beeram M, Tan QT, Tekmal RR, Russell D, Middleton A, De Graffenried LA. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 2007;18:1323-8. (Pubitemid 47305004)
15. Dreyer C, Sablin MP, Faivre S, Raymond E. Topics in mTOR pathway and its inhibitors. Bull Cancer 2009;96:87-94 (Review French).
16. Mounier N, Vignot S, Spano JP. Activité clinique du CCI779 (temsirolimus), inhibiteur de mTOR. Bull Cancer 2006;93:1139-43. (Pubitemid 46032379)
17. Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005;23:5314-22. (Pubitemid 46206985)
18. Baselga J, Roché H, Fumoleau P, et al. Treatment of post menopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combination with temsirolimus: a randomized, 3-arm, phase Ii study. Breast Cancer Res Treat 2005;94:S62.
19. Chow LWC, Sun Y, Jassem J, et al. Phase 3 study of temsirolimus with letrozole in locally advanced or metastatic breast cancer. SABCS meeting 2006 (abstract 6091).
20. Kahan BD, Wong RL, Carter C, et al. A phase I study of a 4- week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients. Transplantation 1999;68:1100-6. (Pubitemid 29517697)
21. Lévy A, Sauvin LA, Massard C, Soria JC. Everolimus (RAD001) and solid tumours: a 2008 summary. Bull Cancer 2008;95:1205-11.
22. O'Reilly T, Vaxelaire J, Muller MJ, et al. In vivo activity of RAD 001, an orally active rapamycin derivative, in experimental tumor models. Proc Am Assoc Cancer Res 2002 (abstract 359).
23. Boulay A, Zumstein-Mecker S, Stephan C, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004;64:252-61. (Pubitemid 38114106)
24. O'Donnell A, Faivre S, Judson I, et al. A phase I study of the oral mTOR inhibitor RAD-001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in patients with solid tumors. Proc Am Soc Clin Oncol 2003 (abstract 802).
25. Tabernero J, Rojo F, Burris H, Casado A, Macarulla T, Jones S. A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor everolimus (RAD001) in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol 2005 (abstract 3007).
26. Awada A, Cardoso F, Fontaine C, et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 2008;44:84-91. (Pubitemid 350256937)
27. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27:2630-7.
28. Bachelot T, Bourgier C, Cropet C, et al. TAMRAD: a GINECO randomized phaseII trial of everolimus in combination with tamoxifen alone in patients with hormone-receptor positive, HER2 negative metastatic breast cancer with prior exposure to aromatase inhibitors. SABCS 2010 (abstract S1-6).